# GPT-5-mini Review

**Role:** External referee review
**Model:** openai/gpt-5-mini
**Paper:** paper.pdf
**Timestamp:** 2026-02-12T12:54:36.834838
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 15415 in / 6210 out
**Response SHA256:** 85b11d3184978ecc

---

Thank you for the opportunity to review. This is an interesting, policy-relevant paper evaluating the Interstate Medical Licensure Compact (IMLC) using modern staggered DiD methods and high-quality administrative data. The topic is important, the data are appropriate, and the use of Callaway & Sant’Anna as the primary estimator is in line with best practice. The main result — precise null effects on state-level healthcare employment, establishments, and wages — is potentially informative for policy debates about interstate licensing and telehealth.

Below I give a comprehensive referee report covering format, statistical methodology, identification, literature, writing quality, constructive suggestions, and an overall assessment. Where I flag problems I distinguish fatal problems from those that are fixable, and I give concrete steps the authors can take.

1. FORMAT CHECK

- Length: The LaTeX source contains a long main text plus extensive appendices. Judging from the amount of material, the paper appears to be at or above the length expected for a top journal submission. I estimate the main text (through Conclusion) is roughly 25–30 pages, with appendices adding substantially more. Please report an explicit page count in the submission (main text pages excluding references and appendices), because some journals require a maximum or minimum. If the manuscript is under 25 pages of main text excluding references/appendix, please expand exposition (see writing suggestions).

- References: The paper cites many of the key recent methodology papers (Callaway & Sant’Anna, Sun & Abraham, Goodman-Bacon) and several applied and policy sources. However, there are a few important methodological and applied references that should be cited and discussed explicitly (see Section 4 below). Also check that the bibliography file (references.bib) actually contains every citation used in the text (some in-text references look like placeholders: e.g., jolinRichman2024; check these entries are real and complete).

- Prose: Major sections (Introduction, Background, Data, Empirical Strategy, Results, Discussion, Conclusion) are written in paragraph form. The Data and Background sections have some itemized lists (acceptable). Overall the structure meets the “prose, not bullets” requirement.

- Section depth: Major sections are generally substantive. The Introduction is long and well-developed (several paragraphs). Empirical Strategy and Results likewise contain multiple substantive paragraphs. Some subsections (e.g., parts of the Discussion) could be expanded slightly, but each major section has 3+ paragraphs.

- Figures: The LaTeX includes \includegraphics commands for figures. In the source I cannot see rendered figures; the figure captions are informative and the text describes the figure results (event studies, cohort ATTs). On a rendered PDF you should verify: axes labeled, units indicated, confidence bands and markers visible, legends readable, and fonts legible. The captions should state the sample, estimator, base period, and clustering used (some do, but check all).

- Tables: The source uses \input{tables/...} for key tables. In the text you report coefficient estimates with SEs and CIs, so it appears tables include real numbers. Before submission ensure all tables have SEs in parentheses, number of clusters and observations, and that any notes explain transformations (log(Y+1)) and how to interpret coefficients.

Summary: Format is broadly fine; ensure bibliography completeness and confirm all figures/tables are clean in the rendered PDF.

2. STATISTICAL METHODOLOGY (CRITICAL)

This is the most important part of the review. A paper cannot pass review without sound statistical inference and appropriate handling of staggered DiD, pre-trends, and small-cluster inference considerations.

a) Standard Errors: PASS. The paper reports standard errors for main coefficients (e.g., healthcare employment ATT = -0.005, SE = 0.010). The tables should show SEs in parentheses and the number of clusters; I recommend adding cluster-robust SEs in tables plus wild-cluster bootstrap p-values as discussed below.

b) Significance Testing: PASS. The paper reports p-values and discusses statistical significance. It also gives 95% CIs for main results in the text.

c) Confidence Intervals: PASS. Main results include 95% CIs (text examples). Ensure all main tables also report 95% CIs or p-values for clarity.

d) Sample Sizes: You report the panel dimensions (51 jurisdictions × 10 years = 510 state-year observations) and number of treated / never-treated states (40 treated, 11 never-treated). For each regression/table also report N (number of state-year observations) and number of clusters (51) explicitly in table notes.

e) DiD with Staggered Adoption: PASS with caveats. You correctly use Callaway & Sant’Anna (2021) as your primary estimator and show Sun & Abraham as a robustness check, and you include a Goodman-Bacon decomposition. This is the current best-practice approach for staggered treatment. Good. However, there are several important robustness and inference steps you should add given the evidence of pre-trends and the comparatively small number of never-treated states:

  - Pre-trends: You document statistically significant positive pre-treatment coefficients at event times k = -5 to -2 (Figure 3 and text). These are potentially worrisome for parallel trends. You discuss plausible explanations (compositional differences, convergence), but additional robustness and sensitivity analysis are required (see Identification section below).

  - Control group choice: The primary CSA estimator uses never-treated units as controls. This is defensible, but the never-treated states differ systematically in size and other covariates (California, New York, etc.). You already report “not-yet-treated” alternative; please present the full CSA results using not-yet-treated as the default comparison and show whether event-study pre-trends persist. Also consider reweighting never-treated states to better match treated states on pre-treatment trends or covariates (see suggestions below).

  - Heterogeneous cohorts / limited post-treatment horizons: You note that later cohorts have short post-treatment windows. CSA handles this, but it remains important to show cohort-specific event studies (you have cohort ATTs) and to show estimates dropping the 2022/2023 cohorts (you report some of this). Continue to emphasize sensitivity to cohort composition.

f) RDD: Not applicable.

Additional methodological points and required fixes:

- Pre-trend sensitivity and honest inference: Given the statistically significant pre-trends several years before treatment, you should implement Ramsey-style sensitivity checks. Specifically:

  - Implement Rambachan & Roth (2023) honest inference / pre-trends sensitivity bounds (or the related methodology in Roth 2023) to quantify how much parallel-trends violation could bias your ATT and to present “robust” confidence intervals that allow for bounded departures from parallel trends.

  - Alternatively, present estimates that include unit-specific linear trends (state × linear time) or flexible state-specific trends (e.g., state × polynomial or spline) and show how ATT and event-study coefficients change. Be cautious: adding trends can soak up treatment variation and bias toward zero if trends are correlated with treatment timing; show results with linear trends, with quadratic trends, and with leave-one-out specifications for robustness.

- Pre-treatment matching / weighting: Consider re-weighting treated and never-treated states so pre-treatment trajectories align better. Options:

  - Entropy balancing or propensity-score weighting on pre-treatment outcomes and covariates (population, initial healthcare employment level, urbanization) to balance pre-trends.

  - Synthetic control / matrix completion / generalized synthetic control (Xu 2017) for cohorts (or aggregated groups). Synthetic DiD (Arkhangelsky et al., 2019) or matrix completion approaches can be helpful if parallel trends are questionable.

- Inference with modest clusters: You cluster at the state level (good). However, with 51 clusters and an imbalance between treated (40) and never-treated (11), conventional cluster-robust SEs can be anti-conservative in small samples. I recommend:

  - Report wild cluster bootstrap p-values for main ATTs and event-study coefficients (Cameron, Gelbach & Miller 2008).

  - Report placebo permutation tests: randomly assign “adoption years” (keeping the same distribution of treated counts across years) and re-estimate ATTs to build a reference distribution under the null.

- Check for treatment effect dynamics and anticipation: The presence of pre-trends at k = -5..-2 suggests possible anticipation (or selection). Investigate whether states show legislative activity prior to operationalization (the treatment coding uses operational adoption year; some states may have passed enabling legislation earlier). If so, you may need to re-code treatment as the year of first legislative signal, or at least show sensitivity to moving the treatment date earlier (placebo earlier treatment). If “adoption” is gradual, consider fuzzy timing and perform a robustness check with alternative coding (e.g., code treatment year as legislative enactment year vs operational year).

- Spillovers: You discuss spillovers qualitatively. Consider testing for spatial spillovers: e.g., exclude border states to see whether effects change, or include a variable for neighboring states’ adoption intensity. At minimum, conduct a robustness check dropping states that share a border with a recently-treated state (or inversely drop states surrounded by many treated neighbors) to assess sensitivity.

- Outcome measurement: You correctly note a key measurement limitation: QCEW records workplace location, not patient location. This must be emphasized and you should be careful in the interpretation: null employment effects do not imply no increases in cross-state telehealth. Suggest additional analyses using claims or provider-level data as future work.

In short: the statistical approach is largely appropriate (CSA + Sun & Abraham), but you must address the pre-trends and small-cluster inference more thoroughly. These are not fatal but they require additional analyses in the revision.

3. IDENTIFICATION STRATEGY

Is identification credible? The staggered DiD with CSA is a reasonable approach, but the evidence of pre-trends and systematic differences between treated and never-treated states requires more scrutiny.

Positive pre-treatment coefficients at event times -5 through -2 are the main identification concern. The author’s arguments that these reflect compositional level differences or convergence are plausible but need empirical support:

- Show raw pre-trend plots for treated vs never-treated states after reweighting on pre-treatment outcomes and covariates (e.g., match on population and log(healthcare employment)).

- Show results when the control group is limited to a subset of never-treated states more similar to treated ones (e.g., drop California and New York, or construct a set of size-matched never-treated states). The sensitivity to such choices will indicate how robust the parallel trends are.

- Provide placebo leads (fake treatments) and report distribution of placebo ATTs. You already do a placebo industry (accommodation) which is helpful; do a time-placebo as well.

- Implement Rambachan & Roth sensitivity bounds and report the largest violation of parallel trends consistent with the data that would change the substantive conclusion (i.e., “minimum violation required to make the ATT economically meaningful”). This helps readers interpret pre-trends.

Other identification points:

- Treatment exogeneity: Adoption timing may be correlated with state-level physician shortages or telehealth demand. Consider controlling for time-varying covariates that may predict both adoption and employment trends (e.g., pre-trend in telehealth permits, state demographic growth, political variables). Alternatively, instrument for adoption timing? Instrumenting state adoption is tough and likely infeasible; better to show robustness to covariate adjustment and weighting.

- SUTVA / spillovers: See methodology section above.

- Multiple outcomes and interpretation: Because QCEW measures where workers are physically located, interpret null employment results explicitly as “no change in where physicians are employed,” not “no change in healthcare provision.” Make this distinction very explicit in the abstract and introduction (I recommend strengthening the abstract to emphasize this measurement limitation so readers aren’t misled).

4. LITERATURE (Provide missing references)

The literature review cites many relevant works (Callaway & Sant’Anna, Sun & Abraham, Goodman-Bacon, Kleiner & Krueger). A few important methodological and applied references should be added or discussed explicitly:

- Rambachan & Roth (2022/2023) on pre-trends sensitivity and honest inference. This is directly relevant given observed pre-trends.

- Cameron, Gelbach & Miller (2008) on wild cluster bootstrap inference for small numbers of clusters.

- Arkhangelsky et al. (2021) — Synthetic DiD (and the generalized synthetic control literature: Abadie et al. 2010 and Xu 2017) — as alternative approaches to deal with non-parallel trends.

- De Chaisemartin & D’Haultfœuille (2020) — alternative discussion on TWFE biases (you cite deChaisemartin 2020; ensure full citation and discuss).

- Papers on telehealth and the IMLC / cross-state practice using claims / provider data, if available. Some of the cited papers (Deyo & Ghosh 2023; Oh & Kleiner 2025) may be working papers or unpublished; ensure to include peer-reviewed or working-paper-level sources on telehealth adoption during COVID-19 and on licensing barriers.

Please add the following recommended citations (BibTeX entries below). I include canonical methodological references and a couple of applied methods papers you should cite and discuss.

Recommended BibTeX entries

- Callaway & Sant’Anna (already cited in text, but include if missing in bib):

```bibtex
@article{callaway2021difference,
  author = {Callaway, Brantly and Sant'Anna, Pedro H. C.},
  title = {Difference-in-Differences with Multiple Time Periods},
  journal = {Journal of Econometrics},
  year = {2021},
  volume = {225},
  pages = {200--230}
}
```

- Sun & Abraham (also cited in text; include full):

```bibtex
@article{sunAbraham2021,
  author = {Sun, Liyang and Abraham, S.},
  title = {Estimating Dynamic Treatment Effects in Event Studies with Heterogeneous Treatment Effects},
  journal = {Journal of Econometrics},
  year = {2021},
  volume = {225},
  pages = {175--199}
}
```

- Rambachan & Roth (honest DiD inference / pre-trend sensitivity):

```bibtex
@article{rambachanRoth2023,
  author = {Rambachan, Ash and Roth, Jonathan},
  title = {Adapting to Pre-Trends and Honest Inference in Difference-in-Differences},
  journal = {Review of Economics and Statistics},
  year = {2023},
  volume = {105},
  pages = {1--18}
}
```

- Cameron, Gelbach & Miller (wild cluster bootstrap):

```bibtex
@article{cameron2008bootstrap,
  author = {Cameron, A. Colin and Gelbach, Jonah B. and Miller, Douglas L.},
  title = {Bootstrap-Based Improvements for Inference with Clustered Errors},
  journal = {Review of Economics and Statistics},
  year = {2008},
  volume = {90},
  number = {3},
  pages = {414--427}
}
```

- Arkhangelsky et al. (Synthetic DiD):

```bibtex
@article{arkhangelsky2021synthetic,
  author = {Arkhangelsky, Dmitry and Athey, Susan and Hirshberg, Daniel and Imbens, Guido and Wager, Stefan},
  title = {Synthetic Difference-in-Differences},
  journal = {Review of Economics and Statistics},
  year = {2021},
  volume = {103},
  number = {5},
  pages = {1--30}
}
```

- Abadie, Diamond & Hainmueller (Synthetic Control):

```bibtex
@article{abadie2010synthetic,
  author = {Abadie, Alberto and Diamond, Alexis and Hainmueller, Jens},
  title = {Synthetic Control Methods for Comparative Case Studies: Estimating the Effect of California's Tobacco Control Program},
  journal = {Journal of the American Statistical Association},
  year = {2010},
  volume = {105},
  pages = {493--505}
}
```

- Xu (Generalized Synthetic Control / Matrix completion):

```bibtex
@article{xu2017generalized,
  author = {Xu, Yiqing},
  title = {Generalized Synthetic Control Method: Causal Inference with Interactive Fixed Effects Models},
  journal = {Political Analysis},
  year = {2017},
  volume = {25},
  number = {1},
  pages = {1--27}
}
```

- Goodman-Bacon (you cite but ensure full citation):

```bibtex
@article{goodmanBacon2021,
  author = {Goodman-Bacon, Andrew},
  title = {Difference-in-Differences with Variation in Treatment Timing},
  journal = {Journal of Econometrics},
  year = {2021},
  volume = {225},
  pages = {254--277}
}
```

Explain why each is relevant (briefly):

- Rambachan & Roth: provides methods to do sensitivity analysis when pre-treatment trends are present; directly relevant because your event study shows pre-trends.

- Cameron et al.: recommended for robust inference with a small number of clusters; use wild cluster bootstrap p-values.

- Arkhangelsky et al., Abadie et al., Xu: alternative estimation approaches (synthetic control / synthetic DiD, matrix-completion) that are more robust when parallel trends do not hold perfectly; they can be used as robustness checks.

5. WRITING QUALITY (CRITICAL)

Overall the paper is well written and the narrative is clear. A few writing-quality suggestions:

a) Prose vs bullets: Mostly fine. The Background section uses itemize lists for IMLC features (acceptable). Ensure the introduction is a tight, compelling hook and not too long.

b) Narrative flow: The paper tells a clear story: motivation → policy → data → method → null finding → interpretation. Strengthen the opening paragraph of the Introduction to make the policy question and the reason why employment outcomes are the relevant (and limited) metric more explicit. Consider a short, two-sentence “what we find” paragraph early on.

c) Sentence quality: Generally crisp. A few long paragraphs could be broken for readability. Try to put the key takeaways at the start of paragraphs (you already do this in many places).

d) Accessibility: The paper uses modern econometric jargon (Callaway-Sant’Anna, TWFE bias, etc.). These are appropriate for the audience, but add brief intuition / one-sentence explanation for readers unfamiliar with staggered DiD pitfalls (e.g., why TWFE can be biased with staggered adoption). You do this partially, but a slightly more extended explanation (1–2 sentences) in Empirical Strategy would help non-specialists.

e) Tables: Ensure notes are comprehensive: specify estimator, control group (never-treated vs not-yet-treated), clustering, base period, transformation (log+1), number of clusters, number of treated units, and sample period. For event-study figures, include a vertical line for treatment year and label event times clearly (k = -5 ... +6).

Minor copy edits:

- The Abstract says the ATT is -0.005 log points (SE = 0.010). Consider adding the implied percentage and job count to make magnitudes clearer (you do in the main text, but a single phrase in the abstract helps).

- The footnote in the title about autonomous generation might be flagged by a journal. Confirm whether this is appropriate to remain.

6. CONSTRUCTIVE SUGGESTIONS (to make the paper more impactful)

The paper is promising. Below are concrete analyses and presentation changes that would substantially strengthen the manuscript.

Empirical/identification robustness (high priority)

1. Address the pre-trends more thoroughly:

   - Implement Rambachan & Roth style sensitivity analysis (honest DiD) to quantify how large a pre-trend violation would need to be to overturn your conclusion. Report the sensitivity frontier for the ATT.

   - Estimate models that include state-specific linear trends and quadratic trends. Present event-study graphs with and without trends. If trends eliminate pre-trend significance and do not change ATT materially, report both.

   - Use reweighting / matching on pre-treatment outcomes (entropy balancing or synthetic control-style weighting) so the treated and never-treated pre-trends align better, and show the ATT under those weights.

2. Alternative estimators:

   - Implement synthetic DiD (Arkhangelsky et al.) or matrix-completion / generalized synthetic control (Xu, 2017) as robustness checks. These methods can perform better when pre-trends exist.

3. Inference:

   - Report wild-cluster bootstrap p-values for the ATT and for key event-study coefficients.

   - Provide permutation/placebo inference by randomizing adoption years (keeping adoption cohort sizes) and reporting the empirical distribution of placebo ATTs.

4. Treatment coding and anticipation:

   - Examine whether states had legislative activity (bills introduced, hearings) prior to operational adoption. If so, run robustness with earlier treatment dates (e.g., date of enactment or date of legislative passage) and show how the event study behaves.

5. Spillovers and heterogeneity:

   - Test for spatial spillovers by excluding adjacent states or by including a variable for neighboring states’ share treated that year.

   - If possible, do a county- or MSA-level analysis, or at least explore border-county heterogeneity (some IMLC effects may concentrate in counties bordering other states). The QCEW has county-level data; if accessible, this would be a powerful extension.

6. Alternative outcomes:

   - The key policy channel is telehealth and cross-state care. If feasible, link to claims data (Medicare fee-for-service or all-payer claims) or use telehealth usage proxies (e.g., CMS telehealth claims counts by provider and patient state) to show whether cross-state telehealth increased. If such data are unavailable, emphasize this as an important limitation and propose concrete future data strategies.

Presentation improvements (medium priority)

1. Explicitly state in the Abstract and Introduction that QCEW measures workplace location and therefore that null employment effects do not rule out increases in cross-state telehealth. Right now this message is present but could be made even clearer at the outset.

2. Move some robustness tables (e.g., not-yet-treated control, excluding 2020–21) from Appendix to main text (or at least summarize them in main tables) to demonstrate stability.

3. Provide a table listing the 11 never-treated states with key statistics (population, pre-treatment healthcare employment, urbanization) to underscore differences between treated and never-treated groups.

4. Clarify the power calculation: you report an MDE of ~1.5% (0.015 log points). Show the assumptions of that calculation (residual variance after fixed effects, effective degrees of freedom) and provide an MDE for a 90% CI as well. Also report the realized standard errors for cohort-specific ATTs so readers can assess which cohort-level effects are undetectable.

7. OVERALL ASSESSMENT

Key strengths

- Important and policy-relevant question: evaluating the IMLC and its effect on healthcare labor markets is timely.

- High-quality administrative data (QCEW) and appropriate use of modern DiD estimators (Callaway & Sant’Anna; Sun & Abraham), plus placebo and robustness checks.

- Clear presentation of null results and thoughtful discussion of interpretation and measurement limitations (especially that QCEW captures where workers are based rather than where patients are served).

Critical weaknesses

- Evidence of positive pre-treatment coefficients in the event study is a substantive identification concern. Though the author provides plausible explanations, the paper needs stronger empirical sensitivity analyses (Rambachan & Roth bounds, state trends, reweighting/synthetic DiD, placebo timing) to convince reviewers that the null is credible.

- Inference: with 51 clusters and only 11 never-treated states, conventional cluster-robust SEs may be fragile. The paper should add wild-cluster bootstrap and permutation inference.

- Control-group comparability: never-treated group differs substantially in size and composition; alternative weighting or matched control groups are needed as robustness.

- Outcome limitation: the QCEW may be poorly suited to capture the primary channel (telehealth). This is not a flaw per se, but it reduces the policy relevance of the null unless supplemented by telehealth- or claims-based outcomes. If these data cannot be obtained, the paper must explicitly emphasize this limitation and reframe conclusions accordingly (which you have started to do).

Specific suggestions for improvement

- Implement the sensitivity and robustness checks listed above, especially Rambachan & Roth honest DiD, unit-specific trends, reweighting / synthetic DiD, synthetic controls and wild-cluster bootstrap.

- Add more granular analyses (county-level/border-county) if possible, or at least show that results are stable when excluding very large never-treated states (CA, NY) or when matching on pre-trends.

- Reword the Abstract to stress the measurement limitation and make clear that the null is with respect to state-level employment, not necessarily to cross-state telehealth volumes.

- Populate the bibliography with the missing methodological references (Rambachan & Roth; Cameron et al.; Arkhangelsky et al.; Abadie et al.; Xu) and any important applied telehealth literature you omitted.

8. DECISION

Given the paper’s merits but also the important identification/inference issues (pre-trends and cluster inference) that need to be addressed, I recommend a substantial revision. The core design is sound and the result is plausible, but the paper must provide additional robustness and honest sensitivity analysis before it can be considered for publication in a top general-interest journal.

DECISION: MAJOR REVISION

(If the authors implement the recommended additional analyses—honest pre-trend sensitivity, alternative estimators/weights, wild-cluster bootstrap inference, and, ideally, a telehealth/claims-based outcome or county-level heterogeneity — the paper could be a strong candidate for acceptance.)